We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amgen Inc | LSE:0R0T | London | Ordinary Share | AMGEN ORD (CDI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.25 | -0.39% | 320.25 | 307.50 | 333.00 | 1,120 | 16:35:28 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 28.19B | 6.72B | 12.5510 | 25.43 | 172.06B |
TIDMTTM
RNS Number : 7284P
Bank of America Merrill Lynch
13 February 2023
FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1. KEY INFORMATION Name of exempt principal trader Bank of America, N.A., Proprietary Company dealt in HORIZON THERAPEUTICS PLC ----------------------------------- Class of relevant security to which the Common - IE00BQPVQZ61 dealings being disclosed relate(Note 1) ----------------------------------- Date of dealing 10/02/2023 ----------------------------------- 2. INTERESTS AND SHORT POSITIONS (a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2) Class of relevant security: Common IE00BQPVQZ61 Long Short ----------------- ----------------- Number % Number % -------- ------- -------- ------- (1) Relevant securities 930,000 0.407% 0 0 % -------- ------- -------- ------- (2) Derivatives (other than options): 26,837 0.012% 882,880 0.386% -------- ------- -------- ------- (3) Options and agreements to purchase/sell: 0 0% 0 0% -------- ------- -------- ------- Total 956,837 0.419% 882,880 0.386% -------- ------- -------- ------- (b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2) Class of relevant security: Long Short ------------ ------------ Number % Number % ------- --- ------- --- (1) Relevant securities 0 0% 0 0% ------- --- ------- --- (2) Derivatives (other than options): 0 0% 0 0% ------- --- ------- --- (3) Options and agreements to purchase/sell: 0 0% 0 0% ------- --- ------- --- Total 0 0% 0 0% ------- --- ------- --- 3. DEALINGS (Note 3) (a) Purchases and sales Purchase/sale Number of relevant securities Price per unit (Note 4) Purchase 47,001 109.15 USD ------------------------------ ------------------------ Purchase 1 109.33 USD ------------------------------ ------------------------ Purchase 1 109.36 USD ------------------------------ ------------------------ Purchase 191 109.42 USD ------------------------------ ------------------------ Purchase 1 109.43 USD ------------------------------ ------------------------ Purchase 1 109.45 USD ------------------------------ ------------------------ Purchase 3,500 109.52 USD ------------------------------ ------------------------ Purchase/sale Number of relevant securities Price per unit (Note 4) Sale 1 109.15 USD ------------------------------ ------------------------ Sale 158 109.46 USD ------------------------------ ------------------------ (b) Derivatives transactions (other than options transactions) Product name, Nature of transaction Number of relevant securities Price per unit e.g. CFD (Note 5) (Note 6) (Note 4) Swaps Reducing a Short Position 158 109.461 USD ---------------------------- ------------------------------ --------------- Swaps Increasing a Short Position 47,000 109.15 USD ---------------------------- ------------------------------ --------------- Swaps Increasing a Short Position 3,500 109.526 USD ---------------------------- ------------------------------ --------------- (c) Options transactions in respect of existing relevant securities (i) Writing, selling, purchasing or varying Product Writing, Number of Exercise Type, Expiry date Option money paid/ received name, selling, securities price e.g. American, per unit (Note 4) e.g. call purchasing, to which European option varying the option etc etc. relates (Note 7) N/A N/A N/A N/A N/A N/A N/A ------------- --------------- --------- ---------------- ------------ ------------------------------ (ii) Exercising Product name, Number of securities Exercise price per e.g. call option unit (Note 4) N/A N/A N/A ---------------------- -------------------- (d) Other dealings (including transactions in respect of new securities) (Note 3) Nature or transaction Details Price per unit (Note 7) (if applicable) (Note 4) N/A N/A N/A --------- --------------------------- 4. OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. None Is a Supplemental Form 38.5(b) attached? (Note 8) No Date of disclosure 13/02/2023 Contact name Frank Lui ----------------------- Telephone number +44207 996 6418 ----------------------- Name of offeree/offeror with which connected AMGEN INC ----------------------- Nature of connection (Note 9) Advisor to - AMGEN INC -----------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ISEFLFVIFTIVLIV
(END) Dow Jones Newswires
February 13, 2023 05:39 ET (10:39 GMT)
1 Year Amgen Chart |
1 Month Amgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions